Baseline 1 month 3 months 6 months 12 months 24 months
Control group Mean (95% CI) 5.83 (5.23-6.43) 5.83 (5.23-6.43) 5.83 (5.23-6.43) 5.83 (5.23-6.43) 5.83 (5.23-6.43) 5.83 (5.23-6.43)
Variance 22.03 16.60 16.60 16.60 16.60 21.58
Intervention group Mean (95% CI) 5.83 (5.23-6.43) 5.83 (5.23-6.43) 5.83 (5.23-6.43) 5.83 (5.23-6.43) 5.83 (5.23-6.43) 8.09 (6.65-9.53)
Variance 22.03 22.47 16.60 16.60 16.60 21.58
Intervention group
Covariances
(and correlations)
Baseline   10.68 (0.48) 7.70 (0.40) 6.88 (0.36) 8.83 (0.46) 3.80 (0.17)
1 month 9.49 (0.50)   9.49 (0.49) 9.49 (0.49) 9.49 (0.49) 9.49 (0.43)
3 months 9.49 (0.50) 9.49 (0.57)   9.49 (0.57) 9.49 (0.57) 9.49 (0.50)
6 months 9.49 (0.50) 9.49 (0.57) 9.49 (0.57)   9.49 (0.57) 9.49 (0.50)
Control group 12 months 9.49 (0.50) 9.49 (0.57) 9.49 (0.57) 9.49 (0.57)   9.49 (0.50)
24 months 9.49 (0.44) 9.49 (0.50) 9.49 (0.50) 9.49 (0.50) 9.49 (0.50)  
1Original coding of the hyperglycaemic episodes was grouped to assist adolescents to estimate their episodes. The midpoint of the range was taken to ensure more meaningful population mean values such that “1-3 days”=2; “4-6 days”=5, “7-12 days”=10 “12 or more”=13
Table 4(b): Population mean (95%CI), variances and covariances from the model of hyperglycaemic episodes as outcome from baseline to 24 months1.